查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179912

2022-2029 年全球sacral神经刺激市场

Global Sacral Nerve Stimulation Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球sacral神经刺激市场规模预计在预测期内（2022-2029 年）以 11.2% 的复合年增长率增长。

sacral神经调节 (SNM) 被数百万患有膀胱过度活动症且对行为矫正和药物治疗有抵抗力的人使用。 SNM 的适应症包括尿潴留、急迫性尿频、急迫性尿失禁和大便失禁。

市场动态

在预测期内，老年人口的增长、市场开发的进步以及sacral神经刺激装置的技术进步正在推动全球sacral神经刺激市场的发展。

世界上日益严重的老龄化人口正在推动全球市场的增长。

膀胱过度活动症 (OAB) 是多种症状的混合体，会导致急迫和频繁的排尿衝动，大多数人在夜间会出现更多的尿失禁。 膀胱过度活动症通常见于 65 岁以上的人群。 女性可以在较早的年龄患上 OAB，通常在 45 岁左右。 残疾或外伤并不是尿失禁的唯一威胁。 随着年龄的增长，自然会发生多种身体变化。 这些变化会影响身体，包括维持排洩的肌肉、器官和神经。 肌肉失去力量，一些神经失去能力，组织器官失去轻微的伸展能力。 因此，随着老年人口的增长，对sacral神经刺激的需求也会增加，这将推动全球市场的增长。 举例 例如，据世界卫生组织统计，2020年老年人口将达到10亿，预计2030年将达到14亿。 另据估计，到 2050 年，老年人口总数将比 2020 年翻一番，即 21 亿。 同样，2020 年至 2050 年期间，80 岁及以上人口预计将增加两倍，达到 4.26 亿。 因此，数据显示，全球老龄化人口的增加将推动预测期内的市场增长。

设备的高成本阻碍了全球市场的增长。

然而，sacral神经刺激的高手术成本和产品成本阻碍了全球市场的增长。 举例 例如，FDA批准并经临床验证的sacral神经刺激疗法（Axonics Therapy）治疗泌尿和肠道功能障碍的平均费用为30,000美元至40,000美元。

COVID-19 的影响

COVID-19 的爆发导致市场下滑，因为大多数非 COVID 治疗援助已停止，以便为 COVID-19 患者提供医疗设施并减少 SARS-CoV-2 病毒的传播。有一个负面影响 例如 例如，根据英国外科杂誌的报导，由于医院服务的严重中断，在 12 週的时间里，大约有 2840 万例择期手术被取消或推迟。 此外，根据论文“关于 COVID-19 对泌尿外科服务影响的全球调查”（2020 年），女性尿失禁、阴囊良性疾病、膀胱结石、不孕症、前列腺增生、肾结石等门诊患者据说处理它的诊所受到大流行的很大影响。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 推进技术创新
      • 老年人口增加
      • 市场策略
    • 约束因素
      • 设备成本高
      • 相关风险
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 嵌入式社交网络
  • 体外 SNS

第 8 章按应用程序类型

  • 大小便失禁
  • 急迫性尿失禁
  • 慢性肛裂
  • 其他

第 9 章最终用户

  • 医院和诊所
  • 门诊手术中心 (ASC)
  • 生命支持中心、疗养院

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准

第12章公司简介

  • 美敦力公司
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Boston Scientific Corporation
  • Jude Medical
  • Cyberonics
  • Neuropace
  • Synapse Biomedical
  • Uroplasty, Inc
  • Codman & Shurtleff, Inc.
  • Axonics Modulation Technologies, Inc.
  • Laborie, Inc

第13章 DataM

简介目录
Product Code: DMMD1675

Market Overview

The global sacral nerve stimulation market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 11.2% during the forecast period (2022-2029).

Sacral neuromodulation (SNM) is performed by millions of people with an overactive bladder which is refractory to behavioral modifications or pharmacotherapy. Indications for SNM enclose urinary retention, urgency frequency, urge incontinence, and fecal incontinence.

Market Dynamics

The growing geriatric population, increased market developments, and technological advancements in sacral nerve stimulation devices are boosting the global sacral nerve stimulation market during the forecast period.

The rising geriatric population globally is fueling the global market growth.

Overactive bladder (OAB) is a blend of manifestations that cause urgent and frequent impulses to urinate, the majority of individuals experience incontinence more at night. Overactive bladder is considered typical in people 65 and older. Females may have OAB at a younger age, normally about 45. Disorders or traumas are not the sole threats to incontinence. With the growing age, multiple physical shifts will transpire intrinsically. These modifications impact the body, including the muscles, organs, and nerves that maintain continence. Muscles will lose their strength, some nerves will not perform uup tothe mark, and tissue and organs will lose the little capacity to extend. Thus, with the growing geriatric population, the demand for sacral nerve stimulation will also increase, boosting the global market growth. For instance, according to WHO, the geriatric population accounted for 1 billion in 2020 and is assumed to reach 1.4 billion by 2030. Also, it is estimated that by 2050 the total geriatric population will double the population in 2020, i.e., 2.1 billion. Similarly, the number of individuals aged 80 years or older is anticipated to triple between 2020 and 2050 to surpass 426 million. Therefore, the mentioned data indicates that the growing global geriatric population will drive market growth during the forecast period.

The high cost of devices will hinder global market growth.

However, the high surgery and product costs of sacral nerve stimulation therapy is hindering the growth of the global market. For instance, the average expense of Axonics Therapy, an FDA-approved, clinically verified Sacral Neuromodulation solution to treat urinary and bowel dysfunction, costs between $30,000 and $40,000.

COVID-19 Impact.

The COVID-19 outbreak negatively affected the market since the majority of Non-COVID therapy assistance was halted to make the healthcare centers available for COVID-19 patients and lower the transmission of the SARS-CoV-2 virus. For instance, according to the British Journal of Surgery, about 28.4 million elective surgeries were withdrawn or delayed over 12 weeks because of extreme hospital service upsets. Moreover, according to an article titled "A Global Survey on the Impact of COVID-19 on Urological Services" (2020), outpatient clinics treating women's urinary incontinence, benign scrotal conditions, bladder stone, infertility, benign prostatic hyperplasia, and renal stone was majorly impacted by the pandemic.

Segment Analysis

The implantable SNS segment is predicted to have a high demand during the forecast period (2022-2029).

The implantable SNS segment is expected to grow at a high CAGR throughout the forecast period as new sacral stimulation implant devices are introduced into the market. For instance, in April 2022, the United States Food and Drug Administration (USFDA) granted clearance to the Axonics F15 device, permitting it to be implanted for 15 years to intercept the irregular nerve impulses associated with overactive bladder and fecal incontinence. Also, in 2022, Medtronic plc received approval from the United States Food and Drug Administration (USFDA) for its InterStim X, the next generation of the InterStim portfolio's recharge-free device. The InterStim system is a developed treatment choice and the most personalized system to provide sacral neuromodulation (SNM) therapy. Likewise, in February 2021, Contura introduced its newest SNM system, Bulkamid, to treat stress urinary incontinence (SUI). Bulkamid is considered one of the best-in-class & well-differentiated urethral bulking products for females suffering from stress urinary incontinence. Bulkamid has exhibited exceptional outcomes across clinical trials & practices, therefore illustrating a highly efficient first-line minimally invasive therapy for patients.

Similarly, in August 2020, the United States Food Drug and Administration (USFDA) approved Medtronic's InterStim Micro neurostimulator, and InterStim SureScan MRI leads for treating patients with bladder and bowel control disorders. The InterStim Micro neurostimulator is implied to treat patients with fecal incontinence, overactive bladders, and non-obstructive urinary retention through sacral neuromodulation therapy. Thus, owing to the increased product introduction, the implants segment is expected to dominate the global sacral neurostimulation market throughout the forecast period.

Geographical Analysis

North America is predicted to command the global sacral nerve stimulation market.

The North American sacral nerve stimulation market is estimated to grow at a high CAGR during the forecast period (2022-2029). The growing geriatric population, increased healthcare spending and the presence of a majority of key market players in this region contribute to the dominance of North America over the global sacral nerve stimulation market. For instance, according to the U.S. Census Bureau's latest estimates, more than 50 million people aged 65 and above live in the U.S., accounting for 16.5% of the population. Among other states, Florida has the largest ratio of senior citizens, about 21%, pursued by Maine with 20%. In contrast, Utah has the most inferior ratio of senior citizens, around 10.8%, followed by Alaska, with 11.1%. Also, California has the largest total geriatric population, more than 5.4 million, and after California, Florida has the second highest total geriatric population, at around 4.2 million. With baby boomers aging, state populations are witnessing an upsurge in citizens over 65. Moreover, according to the Centers for Medicare & Medicaid Services, national healthcare spending grew 2.7%, reaching $4.3 trillion in 2021, or $12,914 per person, which accounted for 18.3% of the Gross Domestic Product (GDP).

Furthermore, the presence of key market players such as Medtronic Plc, Boston Scientific Corporation, Jude Medical, Cyberonics, Neuropace, Synapse Biomedical, Uroplasty, Inc, Codman & Shurtleff, Inc, and Axonics Modulation Technologies, Inc., among others holding most of the global market; ensuring the growth of North American sacral nerve stimulation market at a high CAGR in the forecasted period.

Competitive Landscape

The significant players operating in the global sacral nerve stimulation market are Medtronic Plc, Boston Scientific Corporation, Jude Medical, Cyberonics, Neuropace, Synapse Biomedical, Uroplasty, Inc, Codman & Shurtleff, Inc, Laborie, Inc, and Axonics Modulation Technologies, Inc. The key players are embracing various approaches such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the global growth of the medical supplies and equipment market. For instance, In July 2021, Neuspera Medical scored $65M in a series C funding round for a nerve-stimulating implant to treat overactive bladder.

Medtronic, Plc.

Overview:

Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.

Product Portfolio:

The product portfolio of Medtronic, Plc. for sacral nerve stimulation contains InterStim systems: The InterStim systems implanted neurostimulators electrically stimulate the sacral nerve and are believed to normalize neural communication between the bladder and brain and between the bowel and brain.

The global sacral nerve stimulation market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising Advancements in Technology
      • 4.1.1.2. Growing Geriatric Population
      • 4.1.1.3. Market Strategies
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of devices
      • 4.1.2.2. Associated Risk
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Implantable SNS
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. External SNS

8. By Application Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 8.1.2. Market Attractiveness Index, By Application Type
  • 8.2. Urinary & Fecal Incontinence
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Urge Incontinence
  • 8.4. Chronic Anal Fissure
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals and Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Ambulatory Surgical Centers (ASCs)
  • 9.4. Assisted Living Centers & Nursing Homes

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Medtronic, Plc
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Boston Scientific Corporation
  • 12.3. Jude Medical
  • 12.4. Cyberonics
  • 12.5. Neuropace
  • 12.6. Synapse Biomedical
  • 12.7. Uroplasty, Inc
  • 12.8. Codman & Shurtleff, Inc.
  • 12.9. Axonics Modulation Technologies, Inc.
  • 12.10. Laborie, Inc

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us